Stocktwits on MSN

How Merck is preparing for the patent cliff of its blockbuster cancer drug Keytruda

Merck posted a modest Q4 earnings beat with adjusted EPS of $2.04 on $16.4 billion in revenue. ・The company is planning ...
Fierce Pharma

Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its ...

Merck outlines $70B revenue opportunity by mid-2030s as portfolio transformation accelerates

Q4 2025 earnings call highlights: 2026 guidance, KEYTRUDA LOE risks, $70B pipeline outlook, and new launches—read now.
Yahoo

Moderna and MSD’s cancer vaccine plus Keytruda boosts RFS in melanoma study

Add Yahoo as a preferred source to see more of our stories on Google. Moderna and MSD's mRNA cancer vaccine A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD ...